Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
about
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.Implementing genotype-guided antithrombotic therapy.CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian populationEfficacy of esomeprazole in treating acid-related diseases in Japanese populationsGenotype and allele frequency of CYP2C19*17 in a healthy Iranian populationClinical Application of CYP2C19 Pharmacogenetics Toward More Personalized MedicineTherapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.Development of a High-Resolution Melting Analysis Method for CYP2C19*17 Genotyping in Healthy VolunteersLong-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication ratesComparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.Pharmacogenomics of the triazole antifungal agent voriconazole.Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A ReviewIndividualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy.Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics.Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population.CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population.The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (‑806 C>T) alleles among an Iranian population of different ethnicities.Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
P2860
Q33692784-93C1D6A4-4981-4690-B04F-F4EE91820571Q33849298-0CA547F0-3C08-4413-B98D-74BE28E187D1Q33891049-DB161EDA-86CA-4A87-88CB-3556BAE3F4E2Q33990428-BDE702D0-D125-4970-804E-B8CB105F2378Q34552473-FAD839C3-A486-4989-8092-44FFBA587185Q34706677-AF2E113B-C68C-4A69-9A68-04B56EEA05C3Q35987201-A2484D08-8E0C-4794-91CC-6FA7630CA5D8Q36469405-E1782B26-3A53-4105-BD05-939FF8CD9FD7Q36580034-F4807E31-4BCB-43CD-974B-BB438660A06EQ36608562-C64369D2-51F9-4E35-A993-9F00090F24A8Q37162141-FCD9D50A-4623-4C18-AFEB-D2830789D449Q37176949-045DC3AE-AA04-40BD-B675-78B4573080A3Q37442618-21AB3479-39CC-466C-A92F-7858A731B40CQ37578697-82A9F0A8-8EE4-4881-AAE9-B6267816F5D9Q37625226-398766B6-CC67-4A3D-B183-C1DF5028EA67Q37892536-4DAD8C9D-6C3C-418E-91C8-F660F20A9204Q38031223-2F94EA43-94E2-4D8B-9ACE-FBCAAE12F994Q38032920-F57FD06A-D2B9-434F-B757-857ABD01931AQ38284468-0A867735-93E2-484E-B3A5-5C84679E9C1DQ38616806-DE813387-C78D-4B66-B0EE-8B2DF1DDAC0FQ39014381-5F719D65-8B00-4B9C-A3B6-23E03B17E0A2Q39115196-09C72F5B-C77D-4918-AF08-B3C09B4DF2C7Q39115202-74F32D2B-2AB4-414A-9D36-87A5B49F998BQ39420822-3911AAF1-5879-47C0-8019-8F01C4879179Q39479653-7F1937ED-E1B7-41CD-A663-F0299AEA9E10Q39496600-B2D449D7-6FAD-46D4-8953-EA6265FD875AQ39948342-996D4085-1DB3-46D5-BE14-194F909EC829Q40389903-29BB0F89-B577-47FE-8B5D-AE5218F96A7BQ40569531-85D11388-0BEF-4E8E-A0AD-40DDE095D6C8Q41432957-0E4AE48F-9BFB-4CF3-A94E-348368362EA6Q41631036-E90C1B26-FEF0-4C54-A853-36C957064FB2Q42315488-486399A0-0066-494E-9621-78662ED02A6BQ44149312-7D54F2EB-CFBE-42F2-AE74-93A23ADF3D4AQ44760870-CC261E4F-F0C2-47EE-9032-96B05F2F6507Q44906555-446BC28A-5883-4FB1-8CE9-D864BE6A2FB9Q47232877-150056F1-5287-43C3-8EB9-67BA7DCFA78BQ47652515-0E6EFE2F-862C-4A99-966A-3D830020FB91Q50067945-8F716A42-4C92-4609-BA24-66634082CC66Q50217765-4FC4ABA0-69DC-452C-845C-8F5B7088ECE9Q53665185-B7617AF6-519C-4443-AA83-9061F55566C5
P2860
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
@ast
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
@en
type
label
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
@ast
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
@en
prefLabel
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
@ast
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
@en
P2093
P2860
P1476
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
@en
P2093
Katsuyoshi Sugimoto
Tomonori Tateishi
Tsukasa Uno
P2860
P304
P356
10.1111/J.1365-2125.2007.03057.X
P407
P577
2008-01-30T00:00:00Z